ABEONA THERAPEUTICS INC. — Key Metrics
16 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
EPS (Diluted)
$1
Book Value Per Share
$2
Free Cash Flow Per Share
$-1
Cash Per Share
$1
Revenue Per Share
$0
OCF Per Share
$-1
Return on Equity↑+187.3pts
70.0%
Return on Assets↑+116.9pts
43.3%
Return on Invested Capital↑+24.2pts
-73.7%
Debt to Equity
0.13
Current Ratio↑+104.6% +$4
6.93
Quick Ratio↑+99.1% +$3
6.74
Asset Turnover↑+36.3% +$0
0.04
Days Sales Outstanding↑+5.6% +$21
385.51
Days Payables Outstanding
1879.56
Days Inventory On Hand
1308.71
Cash Conversion Cycle
-185.34
R&D / Revenue↓-830.2pts
460.7%
SBC / Revenue
185.2%
Capex / Revenue↓-1.3pts
137.0%
Working Capital↑+342.0% +$136M
$175M
Net Current Asset Value↑+657.8% +$125M
$145M
Invested Capital↑+323.1% +$137M
$179M
OCF / Net Income↓-238.7% -$2
-1.07
FCF / Net Income↓-244.1% -$2
-1.18
Accruals Ratio (Sloan)↑+91.4pts
67.2%
Net Debt↓-280.6% -$126M
$-171M
Net Debt / EBITDA↑+279.2% +$1
1.97
Interest Coverage↑+2.7% +$1
-23.92
Cash Coverage↓-13.6% -$2
-20.41
Capex Coverage↑+39.5% +$6
-9.57
Tangible Common Equity↑+288.5% +$118M
$159M
TCE / Total Assets↑+21.0pts
72.5%
Goodwill / Total Assets↓-7.8pts
21.5%
NOPAT↓-25.9% -$18M
$-89M
Cash ROIC↑+26.8pts
-69.6%
WC / Revenue↑+1690.3pts
3012.6%
Capex / D&A↑+145.0% +$2
3.13
Reinvestment Rate↓-5.1pts
-6.1%
Asset Growth vs Revenue Growth
-147.9%
Revenue 5Y CAGR↓-37.8pts
-10.3%
Book Value 5Y CAGR↑+24.8pts
9.2%
Stock Price (FY-end)↓-38.0% -$3
$5
Market Cap
$349M
P/E Ratio
4.90
P/S Ratio
59.89
P/B Ratio
2.19
P/TB Ratio
2.19
Enterprise Value
$177M
EV / Sales
30.44
FCF Yield
-24.2%
Shareholder Yield
-3.1%
R&D Yield
7.7%
Capex Yield
2.3%
Graham Number
$8
Shares Variation (YoY)
61.1%
Beta (5Y)↓-30.1% -$0
0.87
Cost of Equity↓-1.9pts
8.8%
Cost of Debt (after tax)
18.6%
WACC
9.4%
ROIC - WACC Spread
-83.1%
52W High↓-91.5% -$78
$7
52W Low↓-42.5% -$3
$4
Trailing Return 1Y↑+71.9pts
-6.4%
Trailing Return 5Y↑+4.8pts
-88.3%
F-Score (Piotroski)↑+100.0% +$2
4.00
Z-Score (Altman)
-1.63
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.